Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors

Published:2015-07-28 Issue:21 Volume:121 Page:3826-3835
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Menzies Alexander M.¹²³,Wilmott James S.¹²,Drummond Martin¹²,Lo Serigne¹²,Lyle Megan¹²,Chan Matthew M. K.⁴,Thompson John F.¹²⁵⁶,Guminski Alex¹²³,Carlino Matteo S.¹²⁴,Scolyer Richard A.¹²⁵,Kefford Richard F.¹²⁴⁷,Long Georgina V.¹²

Affiliation:

1. Melanoma Institute Australia; Sydney Australia

2. The University of Sydney; Sydney Australia

3. Royal North Shore Hospital; Sydney Australia

4. Crown Princess Mary Cancer Centre; Westmead Hospital; Sydney Australia

5. Royal Prince Alfred Hospital; Sydney Australia

6. Mater Hospital; Sydney Australia

7. Macquarie University; Sydney Australia

Funder

Cancer Institute of New South Wales through a fellowship

Sydney Medical School Foundation at the University of Sydney

Australian National Health and Medical Research Council through a fellowship

Australian National Health and Medical Research Council

Cancer Institute of New South Wales, and the Melanoma Institute

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference37 articles.

1. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N Engl J Med.,2011

2. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial;Hauschild;Lancet.,2012

3. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma;Long;N Engl J Med.,2014

4. Improved overall survival in melanoma with combined dabrafenib and trametinib;Robert;N Engl J Med.,2015

5. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma;Larkin;N Engl J Med.,2014

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Continuous response despite reduced dose of trametinib as single agent in an adolescent with a relapsed disseminated pediatric low-grade glioma KIAA1549-BRAF fusion positive: a case report and review of the literature;Frontiers in Oncology;2024-05-23

2. Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy;European Journal of Cancer;2024-01

3. Malignant Melanoma;Holland‐Frei Cancer Medicine;2022-10-21

4. Retrospective review of outcomes associated with metastatic melanoma patients treated with 1st‐line BRAF ‐targeted therapy;Pigment Cell & Melanoma Research;2022-09-25

5. Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre;Pathology;2022-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3